Increasing number of clinical
pipeline studies is expected to boost the Influenza
Therapeutics Market growth during the forecast period. For instance, in
January 2018, Romark Laboratories L.C. initiated the phase 3 clinical trial for
Nitazoxanide to evaluate its efficacy and safety in the treatment of
uncomplicated influenza. Nitazoxanide is a broad-spectrum antiparasitic and
broad-spectrum antiviral drug, used in the treatment of intestinal parasitic
infections caused by Cryptosporidium parvam and Giardia lamblia. This study is
expected to be completed in April 2019.
Influenza is a condition that
causes contagious illness. It is characterized by sudden onset of fever,
headache, sore throat, non-productive cough, and rhinitis. Usually infection
lasts for about a week. Over the course of a flu season, different types and
subtypes of influenza can cause illness in humans. There are four types of
influenza virus such as A, B, C, and D. Influenza A and B virus causes most of
the illness in humans. Prolonged influenza infections can cause severe
complications such as pneumonia, bronchitis, acute respiratory distress,
secondary bacterial infections, and cardiovascular complications. To control
the illness caused by influenza virus, influenza antiviral prescription drugs
can be used.
Influenza Therapeutics Market:
Drivers
New drug approvals for the
treatment of influenza is expected to drive the influenza therapeutics market
growth. For instance, in October 2018, Roche announced that the U.S. Food and
Drug Administration (FDA) approved Xofluza (TM) (baloxavir marboxil) for the
treatment of acute, uncomplicated influenza or flu, in people 12 years of age
and older.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2443
Moreover, in November 2018, Henry
M. Jackson Foundation for the Advancement of Military Medicine, initiated phase
4 clinical trial study for egg-based influenza vaccines to study the realistic
evaluation of influenza vaccine effectiveness in active duty members, military
retirees, and other Department of Defense (DOD) beneficiaries.
Furthermore, rising initiatives
by various sponsors to conduct phase 1 clinical trial to study the safety
parameter of anti-influenza drugs is expected to drive the market growth. For
instance, in October 2018, Emory University started phase 1 clinical trial for
seasonal influenza vaccine. The study has been designed to evaluate the impact
of imprinting and repeated influenza vaccination on adaptive immunity,
transcriptomics, and metabolomics. The study is expected to be completed in
July 2020.
Influenza Therapeutics Market:
Restraints
Influenza vaccines have several
limitations including relatively long production times, limited vaccine
capacity, moderate efficacy in certain people, and lack of cross-reactivity,
which is projected to restrain growth of the influenza therapeutic market
during the forecast period. Moreover, increasing concerns among people about
the side effects of vaccines hamper growth of the influenza therapeutic market.
For instance, in October 2018, according to the National Opinion Research
Centre (NORC) at the University of Chicago survey, around 43% of the adults
were vaccinated and 14% plans to receive the flu shot. However, around 41% of
the American people reported that they are not vaccinated and do not intend to
get vaccinated, as adults were most likely to cite concerns about side effects
of the vaccine.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/influenza-therapeutics-market-2443
Influenza Therapeutics Market:
Regional Analysis
On the basis of region, the
global influenza therapeutics market is segmented into North America, Latin
America, Europe, Asia Pacific, Middle East, and Africa.
Asia Pacific is also expected to
witness significant growth in the influenza therapeutics market, owing to
increasing initiatives by the Asia-Pacific Alliance for the Control of
Influenza (APACI), to reduce the burden of influenza by enhancing control
measures and boosting pandemic preparedness in the region, through the provision
of educational information and activities.
Europe have also gained
significant position in the market, owing to increasing initiatives by European
Medical Association (EMA) during an influenza pandemic season leading to continuous monitoring of safety of centrally
authorized pandemic influenza vaccines and antiviral medicines, and fast-track
review of data for the authorization of pandemic influenza vaccines for use in
all EU Member States. Also, increasing number of public awareness programs for
the prevention and diagnosis of influenza resulted in significant growth of the
influenza therapeutics market in this region.
Key players operating in the
global influenza therapeutic market include Daiichi Sankyo Company,
GlaxoSmithKline plc, Natco Pharma, F. Hoffmann-La Roche Ltd., Teva
Pharmaceutical Industries Ltd., Sandoz International GmbH (Novartis AG), Sun
Pharmaceutical Industries Ltd., BiondVax Pharmaceuticals Ltd., Atriva
Therapeutics Gmbh, Texas Medical Center, Life Science Austria (LISA), GE Healthcare
Life Sciences, Sanofi Pasteur SA and Mylan, Inc.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2443
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment